For laboratory research use only. Not for human or veterinary use, and not for diagnostic or therapeutic application.
Search interest in “FOXO4” and “FOXO4-DRI” overlaps almost completely, and secondary sources routinely treat the two terms as interchangeable. They are not. One is a human transcription factor encoded in the genome; the other is a synthetic peptide built in mirror chemistry and designed to interfere with one of that transcription factor’s protein–protein interactions. Collapsing the two makes the primary literature very difficult to read, because a paper about FOXO4 the protein and a paper about FOXO4-DRI the peptide are frequently describing opposite sides of the same interaction. This guide separates them, explains what the “D-retro-inverso” designation actually specifies at the chemical level, and describes the FOXO4–p53 interaction that motivated the design. It is mechanism only: no protocols, no outcome claims.
One typographic note that costs researchers real time first: the name is FOXO4 — the letter O twice, then the digit 4. It is very commonly mistyped as “FOX04” with a zero, which is why that spelling appears in URLs across the vendor web, including the FOXO4-DRI product page.
FOXO4 and FOXO4-DRI at a glance
| Property | FOXO4 (the transcription factor) | FOXO4-DRI (the synthetic peptide) |
|---|---|---|
| What it is | A full-length protein of the FoxO forkhead family, expressed from a gene on the X chromosome (historically called AFX / AFX1) | A short synthetic peptide, chemically manufactured, corresponding to only a fragment of the FOXO4 sequence |
| Origin | Endogenous; transcribed and translated by the cell | Solid-phase peptide synthesis; not produced by any organism |
| Stereochemistry | L-amino acids, as with essentially all ribosomally synthesised protein | D-amino acids throughout — the mirror image at every chiral centre |
| Sequence direction | Normal N→C order | Reversed (“retro”) relative to the parent fragment |
| Protease handling | Susceptible to normal cellular proteolysis and regulated turnover | Largely resistant, because mammalian proteases are stereospecific for L-configured backbones |
| DNA binding / transactivation | Yes — binds forkhead response elements and regulates transcription | No — it is a fragment with no DNA-binding capability and no transactivation domain |
| Role in the studied interaction | Binds p53 in cell models | Designed to compete with FOXO4 for that same interaction surface |
FOXO4: a forkhead transcription factor
FOXO4 belongs to the FoxO subfamily of forkhead-box transcription factors, alongside FOXO1, FOXO3 and FOXO6. These proteins share a winged-helix DNA-binding domain and act as convergence points for insulin/PI3K–AKT signalling, oxidative-stress signalling and nutrient sensing. Phosphorylation by protein kinase B (AKT) drives FoxO proteins out of the nucleus and shuts down their transcriptional programme — a control mechanism first described directly for FOXO4 under its older name AFX (Kops and colleagues, Nature, 1999). Reviews of the family describe FoxO proteins as signalling integrators involved in cell-cycle arrest, redox handling and stress responses in research models.
Relevant here is a second, non-transcriptional property: FOXO4 has been reported to engage in direct protein–protein contact with p53. Structural and biophysical work on the FOXO4–p53 axis has characterised this as an interaction between intrinsically disordered and structured regions of the two proteins, and has framed it as a regulatory node in cellular senescence (Bourgeois and Madl, FEBS Letters, 2018).
What “D-retro-inverso” actually specifies
DRI is not a brand suffix or a potency grade. It is a precise chemical description of two simultaneous modifications to a parent peptide sequence.
D: the chirality inversion
Every chiral amino acid in the peptide is built from the D-enantiomer rather than the L-enantiomer found in natural protein. The immediate consequence is proteolytic stability: peptidases and proteases evolved against L-configured substrates and are stereospecific, so an all-D peptide is a poor substrate for them. In research settings this has been associated with markedly longer persistence in biological matrices compared with the equivalent all-L peptide.
Retro: the sequence reversal
The residue order is reversed relative to the parent. A parent read A-B-C-D from N-terminus to C-terminus becomes D-C-B-A. On its own, reversal would scramble the presentation of the side chains and destroy the binding surface.
Why the two changes are made together
This is the point that most summaries omit. Inverting chirality and reversing sequence are combined because their geometric effects largely cancel. In the combined retro-inverso isomer, the side chains are restored to approximately the same spatial arrangement as in the parent L-peptide — the topochemical equivalence that makes the strategy work — while the backbone amide bonds now run in the opposite direction. The binding face is preserved; the protease-readable backbone is not.
The honest caveat, well documented in the peptidomimetics literature, is that this equivalence is approximate rather than exact. Because the carbonyl and amide groups swap positions, the backbone hydrogen-bond donor/acceptor pattern differs from the parent. Retro-inverso mimicry has therefore been observed to work best for interactions dominated by side-chain contacts in extended conformations, and to be less faithful where an α-helical backbone geometry carries much of the binding energy (Chorev and Goodman, Accounts of Chemical Research, 1993; Guichard and colleagues, PNAS, 1994; Fischer, Current Protein & Peptide Science, 2003). A DRI analogue is a designed approximation of its parent, not a guaranteed functional copy, and each one has to be characterised empirically.
The FOXO4–p53 interaction the peptide was designed around
Cellular senescence is a stable cell-cycle arrest accompanied by a distinctive secretory phenotype and characteristic marker changes; consensus reviews stress that it is identified by a panel of markers rather than any single one (Gorgoulis and colleagues, Cell, 2019; Hernandez-Segura and colleagues, Trends in Cell Biology, 2018). Senescent cells accumulate p53, yet do not undergo apoptosis at the rate that accumulation alone might predict.
The model advanced by Baar and colleagues (Cell, 2017, volume 169) proposed that FOXO4 binds p53 and helps retain it in nuclear foci in senescent cells, and that this sequestration is part of why those cells remain viable. FOXO4-DRI was designed as a competitive interference peptide: a retro-inverso analogue of the FOXO4 region implicated in that contact, joined to a cell-penetrating import segment so the construct can reach the nuclear compartment in cell models. In those reports, exposure was observed to reduce FOXO4–p53 co-localisation and was associated with p53 nuclear exclusion and apoptosis that was more pronounced in senescent than in non-senescent cells. The design rationale is discussed further in de Keizer, Trends in Molecular Medicine, 2017, volume 23.
Why the two names are not interchangeable
FOXO4-DRI is a fragment-derived antagonist of a FOXO4 interaction. It is not FOXO4 protein, not a source of FOXO4, and not a FOXO4 agonist or activator. It carries no DNA-binding domain and no transactivation domain, so it cannot reproduce FOXO4’s transcriptional function. A study reporting that FOXO4 supports senescent-cell viability and a study reporting that FOXO4-DRI reduces it are consistent with each other, not contradictory — the second is disrupting what the first describes. Reading either as a statement about “FOXO4” generically inverts the mechanism.
Characterisation and handling in the laboratory
Because DRI analogues are non-natural chemistry, identity confirmation matters more than usual: mass spectrometry and purity data should be read from the lot documentation rather than assumed. Molecular weight and CAS values circulating in secondary sources for this peptide are not consistently accurate, so verify identity against the lot record in the COA library rather than a figure quoted online. Reconstitution is ordinary laboratory arithmetic — mass of lyophilised peptide in the vial divided by the volume of solvent added gives the resulting concentration — and the reconstitution calculator performs that calculation. Lyophilised material is generally stored frozen and protected from light; follow the storage conditions stated on the lot documentation.
What the literature does and does not establish
The work described above is preclinical: cell culture and animal models. There are no human clinical data. The foundational characterisation originates from a small number of groups, and the extent to which observed effects depend strictly on the FOXO4–p53 interaction rather than additional pathways remains an open question. The cell-penetrating segment introduces its own variables — uptake efficiency, intracellular distribution and potential off-target interactions — which is why appropriately controlled comparisons, including scrambled and all-L control peptides, appear throughout the methods sections of this literature. Researchers evaluating FOXO4-DRI should treat the mechanism as a working model under active investigation rather than settled biology.
References
- Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017;169(1). (Title omitted; cited by authors, journal, volume and year.)
- de Keizer PLJ. Trends in Molecular Medicine. 2017;23(1). (Title omitted; cited by author, journal, volume and year.)
- Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters. 2018;592(12).
- Eijkelenboom A, Burgering BMT. FOXOs: signalling integrators for homeostasis maintenance. Nature Reviews Molecular Cell Biology. 2013;14(2).
- Kops GJPL, de Ruiter ND, De Vries-Smits AMM, et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999;398.
- Chorev M, Goodman M. A dozen years of retro-inverso peptidomimetics. Accounts of Chemical Research. 1993;26.
- Guichard G, Benkirane N, Zeder-Lutz G, et al. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proceedings of the National Academy of Sciences USA. 1994;91.
- Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Current Protein & Peptide Science. 2003.
- Gorgoulis V, Adams PD, Alimonti A, et al. Cellular Senescence: Defining a Path Forward. Cell. 2019;179(4).
- Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends in Cell Biology. 2018;28(6).
Reviewed for research accuracy — 1 August 2026.
All material discussed here is intended for laboratory research use only. It is not a drug, is not for human or veterinary use, and nothing above should be read as a medical, therapeutic or performance claim.